• Azitra CEO Francisco Salva issued a shareholder letter outlining a strategic pivot toward nearer-term milestones, leveraging March financing of $10.5 million with up to $21 million in warrant proceeds.
• Launched ATR-COSF, a recombinant filaggrin cosmetic-ingredient program; targets fine lines and wrinkles, with a clinical study expected to finish in late 2026.
• Management flagged potential partnership or commercialization for ATR-COSF as soon as 2027, citing shorter development timelines versus therapeutics.
• Expanded into biotech products using FHCC in-licensed microbial engineering tools; initial targets include TEV protease and T7 RNA polymerase, aiming for partnering within 36 months.
• ATR-04 enrollment continues with MD Anderson added as a site; ATR-12 enrollment to be paused to conserve capital and redirect funds to ATR-COSF.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-028994), on June 17, 2026, and is solely responsible for the information contained therein.